Form 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2012

Commission File Number: 001-31368

 

 

SANOFI

(Translation of registrant’s name into English)

 

 

54, Rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F   x             Form 40-F   ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule

101(b)(1):             

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule

101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes   ¨             No   x

If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-                

 

 

 

In February 2012, Sanofi issued the press releases attached hereto as Exhibits 99.1 to 99.3 which are incorporated herein by reference.

Exhibit List

 

Exhibit No.

   

Description

Exhibit 99.1    Press release dated February 8, 2012: Annual Financial Results for 2011.
Exhibit 99.2    Genzyme Product Sales Statement, for the Product Sales Measuring Period ended December 31, 2011.
Exhibit 99.3    Press release dated February 8, 2012: Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex.

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: February 8, 2012       SANOFI
    By   /S/ John Felitti         
      Name: John Felitti
      Title:   Associate Vice President,
     

  Corporate Law, Financial & Securities Law

 

3

Exhibit Index

 

Exhibit No.

   

Description

Exhibit 99.1    Press release dated February 8, 2012: Annual Financial Results for 2011
Exhibit 99.2    Genzyme Product Sales Statement, for the Product Sales Measuring Period ended December 31, 2011.
Exhibit 99.3    Press release dated February 8, 2012: Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex.

 

4